Salvage brachytherapy for recurrent soft tissue sarcoma shows variable control and substantial toxicity

Across seven retrospective studies, reported five-year local control ranged from 18% to 87%, with highly variable severe toxicity.

KEY POINTS

  • This PRISMA-based systematic review identified seven retrospective studies evaluating brachytherapy-based salvage treatment for locally recurrent soft tissue sarcoma of the extremities and trunk. The studies included definitive permanent seed implantation and surgery-associated low- or high-dose-rate brachytherapy, sometimes combined with external-beam reirradiation; ROBINS-I assessments indicated moderate-to-serious risk of bias.
  • Reported five-year local control ranged from 18% to 87%, reflecting major differences in tumor burden, recurrence history, surgery, prior irradiation, and treatment technique. Several cohorts mixed previously irradiated and unirradiated patients or combined brachytherapy with other radiation modalities, preventing reliable pooled estimates of brachytherapy-specific efficacy.
  • In the 40-patient Nori series, salvage surgery followed by temporary Iridium-192 low-dose-rate brachytherapy delivered a median 45 Gy after previous irradiation. Five-year local control was 68% and overall survival 60%; local control was 100% for low-grade tumors versus 40% for high-grade tumors, and five patients (12.5%) required surgery for treatment-related complications.
  • A multicenter series of 120 patients treated with iodine-125 stereotactic ablative brachytherapy, including 107 previously irradiated patients (89.2%), reported a 78.3% objective response rate, 37.9% five-year local control time, and 36.1% five-year overall survival. No grade 3–4 adverse events were reported, but the cohort also included oligometastatic disease and did not separately report outcomes for previously irradiated patients.
  • In the 50-patient Cambeiro series, 26 patients had received previous radiotherapy and underwent salvage surgery with either perioperative HDR brachytherapy or intraoperative electron treatment. Five-year locoregional control was 26% in previously irradiated versus 81% in previously unirradiated patients (p=0.001), while reintervention was more frequent following perioperative brachytherapy than intraoperative electron therapy (50% vs 10%; p=0.02).
  • The Torres series of 62 previously irradiated patients compared wide local excision alone with surgery plus additional radiotherapy, predominantly brachytherapy. Five-year local control was 58% with additional RT versus 39% with surgery alone (p=0.4), but late complications were substantially more frequent (80% vs 17%; p=0.001), and five-year extremity amputation rates were 35% versus 11% (p=0.05).
  • Severe toxicity was highly variable, with reported grade 3–4 complication rates from 0% to 49% across studies. Historical cohorts receiving cumulative doses around 95–115 Gy experienced substantial wound-healing complications, necrosis, and reoperations, including 7 of 14 patients in the Indelicato series; however, the suggested 100–110 Gy cumulative toxicity threshold is derived from heterogeneous retrospective comparisons and should not be interpreted as a validated universal dose constraint.

CLINICAL TAKEAWAY

Brachytherapy remains a potentially useful salvage option for selected patients with locally recurrent soft tissue sarcoma after previous irradiation, particularly when combined with complete surgical resection and when treatment volumes are limited. However, substantial heterogeneity in previous treatments, dosimetry, surgical approaches, and patient selection prevents reliable estimates of comparative efficacy or toxicity, and the proposed cumulative 100–110 Gy threshold requires validation before being used as a clinical planning limit.

SOURCE

Brachytherapy

Browse more research Suggest a correction